Envenoming by snakes is an occupational health hazard often faced by farmers and farm laborers of tropical and subtropical countries like Bangladesh. Snake bite is frequently accidental, faced mostly by rural people. The high fatality rate due to venomous snake bite (around 20%) remain largely unnoticed and not appropriately managed by medical professionals. Lack of awareness of junior doctors regarding scientific treatment of snake bite recommended by national guideline further delays proper treatment of victims.

There are about 82 species of snakes identifiable in Bangladesh of which 28 are known venomous. The major venomous snakes in Bangladesh are Elapidae which includes common cobra (Naja kauthia and Naja naja), king cobra and common krait (Bungarus caerulus), uncommon kraits (Bungarus niger, Bugarus wali), viperidae includes Russell's viper, and pit viper and hydrophidae (the sea snakes). During monsoon season or during flooding fatal snake bite usually comes to notice through media. Surprisingly urban case of venomous snake bites were observed in Dhaka Medical College of Hospital during last large flooding in 2004. Early rapid neurotoxic manifestations are seen in cobra bite with local envenoming and occasionally with or without fang mark. Though krait venom is ten times more lethal than cobra, delayed clinical effects are due to slow absorption of venom being deposited in skin deep or subcutaneous tissue by short and sharp fangs.

Anti-snake venom (ASV) is a specific antidote for venomous snakebite. ASV is most effective when used in appropriate dosage and appropriate indication. Although its efficacy is of no doubt, there is high risk of development of anaphylaxis. Hence ASV should be used only in an indicated case in proper dosage to prevent crisis of its supply. Bangladesh has no venom laboratory (commercial) for extraction of venom or preparing anti-snake venom. There are no pharmaceuticals companies in Bangladesh who have come forward to manufacture this vital medicine. So we turned to India for supplying the ASV as a part of disaster management.

There is no complete national data of snake bite cases in Bangladesh although recently a large survey is being carried out for identifying case load. It is estimated that 4.3 person per 100,000 population are the victims of snake bite in Bangladesh. In Bangladesh polyvalent ASV is available which contain antibody against cobra, Russell's viper, common krait and saw-scaled viper. Exact total amount of venom injected by a snake at the time of bite is unknown but fatal dose is known viz. cobra 120 mg, Russell's viper 150 mg, krait 60 mg. The amount of venom neutralized by one ml of

**Correspondence:** Dr. Md. Robed Amin, Assistant Professor, Department of Medicine, Dhaka Medical College, E-mail: robedamin@yahoo.com
polyvalant ASV is known viz. cobra 0.6 mg, Russell’s viper 0.6 mg, krait 0.45 mg. So empirically total ASV required is 200, 250, 134 respectively. However, the clinical features and outcomes are not as simple as predicted, because every bite does not result in complete envenomation. In Bangladesh commercially produced ASV is not licensed but medicine shops still sell the medicine which comes through black-marketing and the price is very high (a single dose cost about 6000 Taka. The Government purchases the ASV very cheaply from India but doesn’t have consistent supply in adequate amount. Majority of snake bite victims report to government hospitals because ASV is given free-of-cost. Most of the victims delay attending hospital and vital time is lost by attending to ojha and others before critical respiratory problem arises.

Medical officers are not well trained through guideline in our country and has no experience in dealing cases of snake bite before. ASV is utilized poorly due to lack of experience and training. Many times it is avoided in an indicated case due to fear of anaphylaxis but administered to patients when there is no indication.

Though the dose of ASV is not fixed, the indications are known. In our country, empirical dose needed for cobra bite is around 100-200 ml and for krait it is around 300-400 ml. Although a Russell’s viper bite needs around 100-800 ml of ASV, it is not a common venomous snake in Bangladesh and report of such vipers is just matter of academic interest. There is Micro-Elisa kit for detection of snake venom and venom antibody which help us to know the exact circulating venom and need of ASV. This will be of great value in a country like Bangladesh where snake bite is endemic and ASV is always in short supply. ASV neutralizes the circulating venom only and no amount of ASV will neutralize or combine with venom once the venom is attached or adsorbed to target organs i.e. platelets, RBCs, vascular endothelium, renal tubules, muscles and neuromuscular receptors. Early administration of ASV prevents the target organ damage. Damaged organs can be salvaged by routine management protocol. Half-life of ASV varies between 26-96 hours, whereas antigen (venom) may reappear in circulation after as long as 130 hours. The dose of polyvalent ASV needed to neutralize snake venom in many snakes is very high which increases the chance of anaphylaxis. Reduction of requirement of ASV can be achieved by preparing ASV from venoms obtained from snakes caught from relevant areas of the country. The next question arises—is ASV is essential for management of snake envenoming?

In a situation of non-availability of ASV, many cases had recovered with blood transfusion alone. Those cases allergic to ASV recovered with conservative measures i.e. ventilator, blood transfusion, anticholinesterase, thrombin inhibitors, fibrinolytic agents, peritoneal dialysis and inotropes may speed up the recovery. The experience of non-availability of ASV and managing with other measures have save many lives in our country but overall outcome was not as good as when ASV is available. Preparation of safe mono-specific ovine FAB fragment antivenom is more effective and potent and may help to fulfill the requirement of ASV.

Training in appropriate use of ASV according to national guideline should be arranged at all hospital level to ease the crisis of supply of ASV. Early administration of ASV prevents morbidity and mortality. The government should take appropriate steps to ensure constant supply of ASV in our health facility. The training for doctors through national guideline is crucial for management of such cases. The pharmaceuticals companies of our country should take immediate initiatives for manufacturing ASV. We need snake farm development in our country like Thailand, India etc for our enrichment of venoms. Venom laboratory and manufacturing monovalent ASV by identification of venom specific snake species of Bangladesh is the long term solution of this particular non-communicable endemic disease.

References

1. Faiz MA, Rahman MR, Das JC. Neurotoxicity and tissue necrosis following bite by cobra (Naja), 1994, Dhaka Congress.


